|
|
| | 3-Acetyl-DON 13C labeled Basic information |
| Product Name: | 3-Acetyl-DON 13C labeled | | Synonyms: | 3-Acetyldeoxynivalenol-13C17 solution;3-Acetyl-DON 13C labeled;3-Acetyldeoxy Nivalenol-13C17;13C17-3-Acetyl-deoxynicalenol;13C17]-3-Acetyl-deoxynivalenol-25 μg/mL in ACN;3-Acetyldeoxy Nivalenol-13C17 / 13C17-3-Ac-DON | | CAS: | 1217476-81-7 | | MF: | C17H22O7 | | MW: | 355.23 | | EINECS: | 808-632-6 | | Product Categories: | | | Mol File: | 1217476-81-7.mol |  |
| | 3-Acetyl-DON 13C labeled Chemical Properties |
| density | 1.425±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | Fp | 2 °C | | storage temp. | −20°C | | solubility | Acetonitrile: Soluble | | form | Liquid | | color | Colorless to light yellow |
| | 3-Acetyl-DON 13C labeled Usage And Synthesis |
| Uses | 3-Acetyldeoxynivalenol-13C17 is the 13C labeled 3-Acetyldeoxynivalenol (HY-N6685)[1]. 3-Acetyldeoxynivalenol, a trichothecene mycotoxin deoxynivalenol (DON) acetylated derivative[2], is a blood-brain barrier (BBB) permeable mycotoxin[3]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-220. DOI:10.1177/1071100718790255
[2] Kadota T, et al. Comparative study of deoxynivalenol, 3-acetyldeoxynivalenol, and 15-acetyldeoxynivalenolon intestinal transport and IL-8 secretion in the human cell line Caco-2. Toxicol In Vitro. 2013 Sep;27(6):1888-95. DOI:10.1016/j.tiv.2013.06.003
[3] Behrens M, et al. Blood-Brain Barrier Effects of the Fusarium Mycotoxins Deoxynivalenol, 3Acetyldeoxynivalenol, and Moniliformin and Their Transfer to the Brain. PLoS One. 2015 Nov 23;10(11):e0143640. DOI:10.1371/journal.pone.0143640 |
| | 3-Acetyl-DON 13C labeled Preparation Products And Raw materials |
|